Treatment Of Gastrointestinal Bleeding With PuraStat® - Prospective Multicenter-Pilotstudy For The Use of Purastat® for GI-Bleeding

Treatment Of Gastrointestinal Bleeding With PuraStat® - Prospective Multicenter-Pilotstudy For The Use of Purastat® for GI-Bleeding - PuraStat®

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00012480

Enrollment

Registered

2017-07-13

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K21.0 K92.2 K58 K58.8 K92

Interventions

Group 1: single-arm multicenter-study for the use of PuraStat® as a method to achieve bleeding stop and for the indication bleeding prophylaxis

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria were: All gastrointestinal bleedings between Forrest Ib-IIc and lower, large-area bleedings, diffuse bleedings. Subgroup for Forrest Ia bleeding (decision of the treating physician), signed consent of the patients if possible, patients between 18-80 years

Exclusion criteria

Exclusion criteria: Forrest IA-bleedings should be treated conventionally. If the physician recognized an indication for the use of PuraStat® in Forrest IA-bleeding these patients were analyzed as a subgroup

Design outcomes

Primary

Measure	Time frame
Achievement of a sufficient bleeding stop by PuraStat®	—

Secondary

Measure	Time frame
Reduction of the re-bleeding rate, documentation of the risk profile and complication rate of PuraStat®	—

Countries

Germany

Contacts

Public ContactChristian Bojarski

Medizinische Klinik mit Schwerpunkt Gastroenterologie, Infektiologie, RheumatologieZentrale Endoskopioe

endo-cbf@charite.de030/8445-2627

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 6, 2026